Case ID: f-appx_538/html/0902-01.html
Source: Caselaw Access Project
Author: {"author": "PER CURIAM.", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

E8 PHARMACEUTICALS, LLC and The Massachusetts Institute of Technology, Plaintiffs-Appellants, v. AFFYMETRIX, INC. and Navigenics, Inc., Defendants-Appellees.
    No. 2013-1046.
    United States Court of Appeals, Federal Circuit.
    Nov. 6, 2013.
    John B. Wyss, Wiley Rein LLP, of Washington, DC, argued for plaintiffs-appellants. With him on the brief were James H. Wallace, Jr., Mark A. Pacella, and Gregory R. Lyons.
    Peter E. Root, Kaye Scholer LLP, of Palo Alto, CA, argued for defendants-ap-pellees. With him on the brief were Michael J. Malecek, Sean M. Boyle, and Gary Ross Allen.
    Before LOURIE, DYK, and O’MALLEY, Circuit Judges.
   PER CURIAM.

We affirm the judgment of noninfringement in favor of Affymetrix, Inc. and Navi-genics, Inc. We base our decision solely on our agreement with the district court’s construction of the phrase “randomly primed PCR-derived RCG.” We do not reach any other issues raised on appeal.

AFFIRMED